ATE547106T1 - CLADRIBINE DOSAGE SCHEME FOR THE TREATMENT OF MULTIPLE SCLERosis - Google Patents

CLADRIBINE DOSAGE SCHEME FOR THE TREATMENT OF MULTIPLE SCLERosis

Info

Publication number
ATE547106T1
ATE547106T1 AT05823474T AT05823474T ATE547106T1 AT E547106 T1 ATE547106 T1 AT E547106T1 AT 05823474 T AT05823474 T AT 05823474T AT 05823474 T AT05823474 T AT 05823474T AT E547106 T1 ATE547106 T1 AT E547106T1
Authority
AT
Austria
Prior art keywords
multiple sclerosis
cladribine
treatment
dosage scheme
preparation
Prior art date
Application number
AT05823474T
Other languages
German (de)
Inventor
Luca Giampiero De
Arnaud Ythier
Alain Munafo
Maria Lopez-Bresnahan
Original Assignee
Merck Serono Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Serono Sa filed Critical Merck Serono Sa
Priority claimed from PCT/EP2005/056954 external-priority patent/WO2006067141A1/en
Application granted granted Critical
Publication of ATE547106T1 publication Critical patent/ATE547106T1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Chemical And Physical Treatments For Wood And The Like (AREA)
  • Pressure Welding/Diffusion-Bonding (AREA)

Abstract

The present invention is related to the use of Cladribine for the preparation of a pharmaceutical formulation for the treatment of multiple sclerosis, especially relapsing-remitting multiple sclerosis or early secondary progressive multiple sclerosis, wherein the preparation is to be the orally administered and wherein re-treatments are possible.
AT05823474T 2004-12-22 2005-12-20 CLADRIBINE DOSAGE SCHEME FOR THE TREATMENT OF MULTIPLE SCLERosis ATE547106T1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US63866904P 2004-12-22 2004-12-22
EP04106909 2004-12-22
PCT/EP2005/056954 WO2006067141A1 (en) 2004-12-22 2005-12-20 Cladribine regimen for treating multiple sclerosis

Publications (1)

Publication Number Publication Date
ATE547106T1 true ATE547106T1 (en) 2012-03-15

Family

ID=34930135

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05823474T ATE547106T1 (en) 2004-12-22 2005-12-20 CLADRIBINE DOSAGE SCHEME FOR THE TREATMENT OF MULTIPLE SCLERosis

Country Status (10)

Country Link
AT (1) ATE547106T1 (en)
DK (1) DK1827461T3 (en)
ES (4) ES2382554T3 (en)
HU (1) HUE035859T2 (en)
LT (1) LT2805723T (en)
ME (1) ME01333B (en)
PT (3) PT2805723T (en)
RS (1) RS52219B (en)
SI (1) SI1827461T1 (en)
UA (1) UA96260C2 (en)

Also Published As

Publication number Publication date
ES2428741T3 (en) 2013-11-11
PT1827461E (en) 2012-05-07
UA96260C2 (en) 2011-10-25
ME01333B (en) 2013-12-20
LT2805723T (en) 2018-02-12
PT2805723T (en) 2018-01-25
ES2495392T3 (en) 2014-09-17
PT3332789T (en) 2022-07-05
HUE035859T2 (en) 2018-05-28
DK1827461T3 (en) 2012-03-26
SI1827461T1 (en) 2012-05-31
ES2382554T3 (en) 2012-06-11
ES2666146T3 (en) 2018-05-03
RS52219B (en) 2012-10-31

Similar Documents

Publication Publication Date Title
EA200700362A1 (en) CONJUGAT, CONTAINING ANTI-VIRUS COMPOUND, IN PARTICULAR INHIBITING HIV, PHARMACEUTICAL COMPOSITION AND SET OF STANDARD DOSE OF THE MEDICINAL DRUG ON ITS BASIS, METHOD OF INHIBITING THE SOFTWARE PRO.
MA38380A1 (en) Quinazoline inhibitors of activation of mutant forms of epidermal growth receptor (EGFR)
MX2013010795A (en) 1,3 oxazines as bace1 and/or bace2 inhibitors.
EA201391786A1 (en) HALOGEN-ALKYL-1,3-OXAZINS AS BACE1 AND / OR BACE2 INHIBITORS
EP1673078A4 (en) Benzylether and benzylamino beta-secretase inhibitors for the treatment of alzheimer's disease
EA201391670A1 (en) 1,3-oxazines as BACE1 and / or Bace2 inhibitors
EA200701296A1 (en) 3,5-Disposable and 3,5,7-triple-substituted 3H-oxazolo-and 3H-thiazolo [4,5-D] pyrimidin-2-she and their medicines
EP1562897A4 (en) Phenylcarboxamide beta-secretase inhibitors for the treatment of alzheimer s disease
EP1841426A4 (en) Tertiary carbinamines having substituted heterocycles, which are active as inhibitors of beta-secretase, for the treatment of alzheimer's disease
EA200601846A1 (en) CONTAINING BENZOXASINS MEDICINAL COMBINATIONS FOR THE TREATMENT OF DISEASES OF RESPIRATORY TRACKS
MX2013008213A (en) N-[3-(5-amino-3,3a,7,7a-tetrahydro-1h-2,4-dioxa-6-aza-inden-7-yl )-phenyl]-amides as bace1 and/or bace2 inhibitors.
PH12014501334A1 (en) Fluoromethyl-5,6-dihydro-4h-[1,3]oxazines
SG160391A1 (en) Cladribine regimen for treating multiple sclerosis
TW200722081A (en) New therapeutic combinations for the treatment or prevention of depression
ATE486587T1 (en) FORMULATIONS FOR THE ORAL ADMINISTRATION OF ACTIVE INGREDIENTS
SG158863A1 (en) Intravenous formulations of pde-5 inhibitors
EA200601212A1 (en) PHOSPHODESTERASE INHIBITORS, OBTAINING AND THEIR THERAPEUTIC APPLICATION
MX2014003408A (en) N-(3-(2-amino-6,6-difluoro-4,4a,5,6,7,7a-hexahydro-cyclopenta[e] [1,3]oxazin-4-yl)-phenyl)-amides as bace1 inhibitors.
ATE543491T1 (en) COMBINATION PREPARATION CONTAINING IBUPROFEN AND PARACETAMOL
DE502005008971D1 (en) SUBSTITUTED 1,4,8-TRIAZASPIROÄ4.5 DECAN-2-ON COMPOUNDS FOR THE TREATMENT OF FAT
EA201591541A1 (en) BETA SECRETASE INHIBITORS 1 (BACE 1)
TW200640465A (en) New pharmaceutically active compounds for the treatment of respiratory diseases
EA200401319A1 (en) NEW HETEROCYCLIC COMPOUNDS, METHODS FOR THEIR PRODUCTION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS AND THEIR USE IN MEDICINE
ATE499933T1 (en) USE OF BETAIN TO TREAT INTERMITTENS CLAUDICATIO
HK1107699A1 (en) Ritonavir analogous compound useful as retroviral protease inhibitor, preparation of the ritonavir analogous compound and pharmaceutical composition for the ritonavir analogous compound